Feed ZLAB
ZL

Zai Lab ZLAB · NASDAQ

$24.03 +9.03% (+$1.99)

Market cap
$2.46B
Enterprise value
$2.11B
P/E
-
Forward P/E
-
PEG
-
P/S
5.5x
P/FCF
-
EV/EBITDA
-
ROIC
-29.3%
Gross margin
56.5%
Net margin
-41.9%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.83
Free float
93.4%

About the company

Zai Lab Limited is a Chinese biotechnology company specializing in the development and commercialization of innovative drugs focused on the treatment of oncology and autoimmune diseases. The company concentrates on developing products in the fields of immunotherapy, targeted therapy, and other advanced treatment methods. Zai Lab collaborates with leading global pharmaceutical and biotechnology companies to bring the latest treatment options to the Chinese market and the broader Asia region, ensuring that patients have access to new therapies.

Sector

Healthcare

Industry

Biotechnology

CEO

Ying Du

Employees

1,784

Headquarters

Shanghai

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy